{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:38:48Z","timestamp":1792805928104,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Women\u2019s Cancer\u2019s Program"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA33572"],"award-info":[{"award-number":["P30 CA33572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a laparoscopic locoregional treatment for peritoneal metastases (PM) from colorectal cancer (CRC) or appendiceal cancer (AC) in patients who cannot undergo cytoreductive surgery (CRS). While PIPAC has been studied in Europe and Asia, it has not been investigated in the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      We evaluated PIPAC with 90 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      oxaliplatin alone (cycle 1) and preceded by systemic chemotherapy with fluorouracil (5-FU) and leucovorin (LV) (cycle 2\u20133) as a multicenter prospective phase I clinical trial (NCT04329494). The primary endpoint was treatment-related adverse events (AEs). Secondary endpoints included survival and laparoscopic, histologic, and radiographic response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>12 patients were included: 8 with CRC and 4 with AC. Median prior chemotherapy cycles was 2 (interquartile range (IQR) 2\u20133). All patients were refractory to systemic oxaliplatin-based chemotherapy. Median peritoneal carcinomatosis index (PCI) was 28 (IQR 19\u201332). Six (50%) of twelve patients completed three PIPAC cycles. No surgical complications or dose-limiting toxicities were observed. Two patients developed grade 3 treatment-related toxicities (one abdominal pain and one anemia). Median overall survival (OS) was 12.0 months, and median progression-free survival (PFS) was 2.9 months. OS was correlated with stable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria but not with laparoscopic response by PCI or histologic response by peritoneal regression grading system (PRGS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This phase I trial in the USA demonstrated safety, feasibility, and early efficacy signal of PIPAC with oxaliplatin and chemotherapy in patients with PM from AC or CRC who are refractory to standard lines of systemic chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-023-13941-2","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T13:03:09Z","timestamp":1690462989000},"page":"7814-7824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA"],"prefix":"10.1245","volume":"30","author":[{"given":"Mustafa","family":"Raoof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raechelle","family":"Tinsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghee","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Benjamin","family":"Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Cristea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Rodriguez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Meera","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Deperalta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Merchea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh H.","family":"Dellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"12","key":"13941_CR1","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/s1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709\u201319. https:\/\/doi.org\/10.1016\/s1470-2045(16)30500-9.","journal-title":"Lancet Oncol"},{"issue":"2","key":"13941_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/s1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/s1470-2045(20)30599-4.","journal-title":"Lancet Oncol"},{"issue":"2","key":"13941_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass W, Kerb R, M\u00fcrdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553\u20139. https:\/\/doi.org\/10.1245\/s10434-013-3213-1.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"13941_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1515\/pp-2017-0015","volume":"2","author":"C Eveno","year":"2017","unstructured":"Eveno C, Haidara A, Ali I, Pimpie C, Mirshahi M, Pocard M. Experimental pharmacokinetics evaluation of chemotherapy delivery by PIPAC for colon cancer: first evidence for efficacy. Pleura Peritoneum. 2017;2(2):103\u20139. https:\/\/doi.org\/10.1515\/pp-2017-0015.","journal-title":"Pleura Peritoneum"},{"key":"13941_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010034","author":"G Nadiradze","year":"2019","unstructured":"Nadiradze G, Horvath P, Sautkin Y, et al. Overcoming drug resistance by taking advantage of physical principles: pressurized intraperitoneal aerosol chemotherapy (PIPAC). Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers12010034.","journal-title":"Cancers"},{"issue":"12","key":"13941_CR6","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.ejso.2019.05.007","volume":"45","author":"O Sgarbura","year":"2019","unstructured":"Sgarbura O, H\u00fcbner M, Alyami M, et al. Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: a multicenter study. Eur J Surg Oncol. 2019;45(12):2386\u201391. https:\/\/doi.org\/10.1016\/j.ejso.2019.05.007.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"13941_CR7","doi-asserted-by":"publisher","first-page":"20180120","DOI":"10.1515\/pp-2018-0120","volume":"3","author":"F Dumont","year":"2018","unstructured":"Dumont F, Senellart H, Pein F, et al. Phase I\/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design. Pleura Peritoneum. 2018;3(3):20180120. https:\/\/doi.org\/10.1515\/pp-2018-0120.","journal-title":"Pleura Peritoneum"},{"key":"13941_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2020.09.010","volume":"140","author":"F Dumont","year":"2020","unstructured":"Dumont F, Passot C, Raoul JL, et al. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. Eur J Cancer (Oxford, England: 1990). 2020;140:37\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.010.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"7","key":"13941_CR9","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1078-0432.Ccr-20-2152","volume":"27","author":"G Kim","year":"2021","unstructured":"Kim G, Tan HL, Sundar R, et al. PIPAC-OX: a phase I study of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal metastases. Clin Cancer Res. 2021;27(7):1875\u201381. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2152.","journal-title":"Clin Cancer Res"},{"key":"13941_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051060","author":"M Robella","year":"2021","unstructured":"Robella M, De Simone M, Berchialla P, et al. A phase I dose escalation study of oxaliplatin, cisplatin and doxorubicin applied as PIPAC in patients with peritoneal carcinomatosis. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13051060.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"13941_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ejso.2021.10.028","volume":"48","author":"M H\u00fcbner","year":"2022","unstructured":"H\u00fcbner M, Alyami M, Villeneuve L, et al. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: technical aspects and treatment protocols. Eur J Surg Oncol. 2022;48(4):789\u201394. https:\/\/doi.org\/10.1016\/j.ejso.2021.10.028.","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"13941_CR12","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.1245\/s10434-022-11577-2","volume":"29","author":"A Taibi","year":"2022","unstructured":"Taibi A, Sgarbura O, H\u00fcbner M, et al. Feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy with or without intraoperative intravenous 5-fluorouracil and leucovorin for colorectal peritoneal metastases: a multicenter comparative cohort study. Ann Surg Oncol. 2022;29(8):5243\u201351. https:\/\/doi.org\/10.1245\/s10434-022-11577-2.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"13941_CR13","doi-asserted-by":"publisher","first-page":"e204787","DOI":"10.1001\/jamanetworkopen.2020.4787","volume":"3","author":"PH Frankel","year":"2020","unstructured":"Frankel PH, Chung V, Tuscano J, et al. Model of a queuing approach for patient accrual in phase 1 oncology studies. JAMA Netw Open. 2020;3(5):e204787\u2013e204787. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.4787.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"13941_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1245\/s10434-021-10505-0","volume":"29","author":"M Raoof","year":"2022","unstructured":"Raoof M, Malhotra G, Kohut A, et al. PIPAC for the treatment of gynecologic and gastrointestinal peritoneal metastases: technical and logistic considerations of a phase 1 trial. Ann Surg Oncol. 2022;29(1):175\u201385. https:\/\/doi.org\/10.1245\/s10434-021-10505-0.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"13941_CR15","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.clcc.2015.12.006","volume":"15","author":"LG Razenberg","year":"2016","unstructured":"Razenberg LG, van Gestel YR, Lemmens VE, de Hingh IH, Creemers GJ. Bevacizumab in addition to palliative chemotherapy for patients with peritoneal carcinomatosis of colorectal origin: a nationwide population-based study. Clin Colorectal Cancer. 2016;15(2):e41\u20136. https:\/\/doi.org\/10.1016\/j.clcc.2015.12.006.","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"13941_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/jco.2011.37.1039","volume":"30","author":"J Franko","year":"2012","unstructured":"Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263\u20137. https:\/\/doi.org\/10.1200\/jco.2011.37.1039.","journal-title":"J Clin Oncol"},{"issue":"3","key":"13941_CR17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1245\/s10434-019-08064-6","volume":"27","author":"O Moaven","year":"2020","unstructured":"Moaven O, Votanopoulos KI, Shen P, et al. Health-related quality of life after cytoreductive surgery\/HIPEC for mucinous appendiceal cancer: results of a multicenter randomized trial comparing oxaliplatin and mitomycin. Ann Surg Oncol. 2020;27(3):772\u201380. https:\/\/doi.org\/10.1245\/s10434-019-08064-6.","journal-title":"Ann Surg Oncol"},{"issue":"9863","key":"13941_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0140-6736(12)61900-x","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2013;381(9863):303\u201312. https:\/\/doi.org\/10.1016\/s0140-6736(12)61900-x.","journal-title":"Lancet (London, England)"},{"issue":"20","key":"13941_CR19","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1414325.","journal-title":"N Engl J Med"},{"issue":"6","key":"13941_CR20","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1007\/s00330-019-06524-x","volume":"30","author":"I van \u2018t Sant","year":"2020","unstructured":"van \u2018t Sant I, Engbersen MP, Bhairosing PA, et al. Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis. Eur Radiol. 2020;30(6):3101\u201312. https:\/\/doi.org\/10.1007\/s00330-019-06524-x.","journal-title":"Eur Radiol"},{"issue":"1","key":"13941_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11547-016-0682-x","volume":"122","author":"A Laghi","year":"2017","unstructured":"Laghi A, Bellini D, Rengo M, et al. Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis. La Radiologia Medica. 2017;122(1):1\u201315. https:\/\/doi.org\/10.1007\/s11547-016-0682-x.","journal-title":"La Radiologia Medica"},{"issue":"2","key":"13941_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1515\/pp-2016-0011","volume":"1","author":"W Solass","year":"2016","unstructured":"Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum. 2016;1(2):99\u2013107. https:\/\/doi.org\/10.1515\/pp-2016-0011.","journal-title":"Pleura Peritoneum"},{"issue":"7","key":"13941_CR23","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/his.13829","volume":"74","author":"W Solass","year":"2019","unstructured":"Solass W, Sempoux C, Carr NJ, et al. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology. 2019;74(7):1014\u201324. https:\/\/doi.org\/10.1111\/his.13829.","journal-title":"Histopathology."},{"issue":"4","key":"13941_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/his.14092","volume":"77","author":"N Benzerdjeb","year":"2020","unstructured":"Benzerdjeb N, Durieux E, Tantot J, et al. Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. Histopathology. 2020;77(4):548\u201359. https:\/\/doi.org\/10.1111\/his.14092.","journal-title":"Histopathology."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13941-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13941-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13941-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:08:24Z","timestamp":1696864104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13941-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["13941"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13941-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"28 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The aerosolizing CapnoPen from CapnoMed were provided without cost for the trial. CapnoMed had no input in the design, conduct, results, or decision to publish results of the study. The authors have no other disclosures. Dr. Richard Whelan: Northwell, my employer, is one of three sites where the study was done. COH provided clinical trial organization and trial monitoring virtually, but no funds were transferred. Also, the Thomphson Family Foundation has given to Northwell $85,000 in the last 18 months to be used to help cover some of the trial costs at the Northwell Site. Dr. Yanghee Woo: Consultant to J&J Ethicon. Dr. Yuman Fong: scientific advisor to Medtronics, Imugene, Vergent Biosciences, XDemics, Theromics, Eureka Biologics, AND Iovance Biotherapeutics; receives royalties from Merck and Imugene. Dr. Joseph Chao: Merck research payments to institution; Brooklyn Immunotherapeutics research payments to institution; Lilly consulting fees paid to me; Merck consulting fees paid to me; AstraZeneca consulting fees paid to me; Foundation Medicine consulting fees paid to me; Daiichi Sankyo consulting fees paid to me; Amgen consulting fees paid to me; Bristol-Myers Squibb consulting fees paid to me; Astellas consulting fees paid to me; Turning Point Therapeutics consulting fees paid to me; Silverback Therapeutics consulting fees paid to me; Novartis consulting fees paid to me; Coherus Biosciences consulting fees paid to me; Geneos consulting fees paid to me; Roche consulting fees paid to me; Guardant Health consulting fees paid to me; Merck speakers bureau honoraria paid to me; Bristol-Myers Squibb speakers bureau honoraria paid to me; Yiviva DSMB member fees paid to me; Daiichi-Sankyo DSMB member fees paid to me.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}